Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Project Oncology®Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Charles Turck, PharmD, BCPS, BCCCP
Petros Grivas, MD, PhD
Real-World Cases in Squamous Cell Carcinoma of the Anal Canal Care
Project Oncology®Real-World Cases in Squamous Cell Carcinoma of the Anal Canal Care
Brian P. McDonough, MD, FAAFP
Madison Conces, MD
Midhun Malla, MD
Making Mechanism-Based Treatment Decisions in cGVHD
Project Oncology®Making Mechanism-Based Treatment Decisions in cGVHD
Brian P. McDonough, MD, FAAFP
Alicia Lieberman, MD, MS
Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care
Project Oncology®Getting Biomarker Testing Right in Non-Small Cell Lung Cancer Care
Raghava Reddy Induru, MD
Choosing the Right Treatment in ALK and ROS1-Positive NSCLC
Project Oncology®Choosing the Right Treatment in ALK and ROS1-Positive NSCLC
Raghava Reddy Induru, MD
ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Project Oncology®ctDNA-Guided Adjuvant Atezolizumab in MIBC: IMvigor011 Insights
Charles Turck, PharmD, BCPS, BCCCP
Guru P. Sonpavde, MD
- advertisement
- 4 questions
- 3 questions
- 4 questions
- 2 questions
- 10 questions
- 4 questions
- advertisement
Expanding Treatment Options in PNH: Expert Approaches to Personalized Care
Medical Industry FeatureExpanding Treatment Options in PNH: Expert Approaches to Personalized Care
Caroline Piatek, MD
Bhumika Patel, MD
Long-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
Medical Industry FeatureLong-Term PNH Management: Addressing Treatment Goals Beyond Symptom Control
Arati Chand, MD
Bhumika Patel, MD
Understanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
Medical Industry FeatureUnderstanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Project Oncology®On the Frontline: Empowering IO Therapies for Patients with HER2-Negative G/GEJC
Charles Turck, PharmD, BCPS, BCCCP
Jun Gong, MD
Evaluating EFS and Surgical Outcomes in Resectable NSCLC: Insights From a Clinical Trial
Medical Industry FeatureEvaluating EFS and Surgical Outcomes in Resectable NSCLC: Insights From a Clinical Trial
Early CAR T Cell Therapy Referral: The Missing Piece in Blood Cancer Treatment
Project Oncology®Early CAR T Cell Therapy Referral: The Missing Piece in Blood Cancer Treatment
- 05/08/2026
- 05/08/2026
- 05/07/2026
- 05/06/2026
- 05/05/2026
- 05/04/2026